

Breakthrough Bio

10 Israeli Startups

Pharma & Medical Devices

A milestone-driven accelerator that gets Israel's most promising pharma (biotech) and medical devices (medtech) founders U.S.-ready. Over six months, MassChallenge helps you strengthen R&D, build the evidence, and form the relationships that move markets.

TWO TRACKS, ONE COHORT

Pharma (Biotech)

Therapeutic development, such as small molecule, biologic, cell therapy, or gene therapy. Focus on evidence, clinical and regulatory readiness, financing, and pharma partnering.

Medical Devices (Medtech)

Medical device, diagnostic, imaging, surgical, wearable, implantable, or connected/software-enabled device. Focus on the U.S. healthcare system, FDA pathways, reimbursement, and go-to-market.

THE PROGRAM JOURNEY • WHAT TO EXPECT AND WHEN

PHASE 1 • PRE-KICKOFF Readiness & Prep

Get Ready

VIRTUAL

Once selected, you complete individualized intake, have a 1-on-1 call with the MassChallenge team, begin to draft goals and milestones for the program, and start planning travel for the in-person elements.

PHASE 2 • WK OF JAN 11 Boston Kickoff

Immerse in the U.S. Ecosystem

IN-PERSON • BOSTON

In-person kickoff and Boston ecosystem immersion: orientation, mentor introductions and kickoff sessions, enterprise-readiness review, targeted workshops, site visits, and curated convenings with operators, investors, and institutions.

PHASE 3 • JAN 18–MAR 12 Build the Evidence

Turn Learnings Into Live Conversations

VIRTUAL

Bi-weekly mentor sessions and expert deep-dives; convert early learnings into active partner, investor, regulatory, clinical, and commercialization conversations. Milestone tracking throughout.

PHARMA (BIOTECH)

Advance clinical, regulatory, and pharma-partnering plans.

MEDICAL DEVICES (MEDTECH)

Prepare for LSI USA '27: sharpen narrative and target meetings.

PHASE 4 • WK OF MAR 15 Meet the Market

California Market Access Sprint

IN-PERSON • SAN DIEGO

Second concentrated U.S. engagement, anchored in San Diego, with curated 1:1s, ecosystem convenings, and investor and business-development meetings tailored to each track.

PHARMA (BIOTECH)

San Diego biotech & life-sciences ecosystem, pharma BD, and investor meetings.

MEDICAL DEVICES (MEDTECH)

Attend LSI USA '27 in Dana Point, CA, the center point of the visit.

PHASE 5 • MAR 22–JUN 4 Convert Momentum

Follow Up and Refine

VIRTUAL

Continued mentoring, targeted introductions, follow-ups from connections made during the Boston and San Diego ecosystem immersion experiences, final pitch refinement, and media preparation, with track-specific readiness for the finale and conference engagement.

PHASE 6 • WK OF JUN 7 Graduate

Finale, Demo Day & Conference Activation

IN-PERSON • PHILADELPHIA

MassChallenge-hosted finale in Philadelphia, replete with regional ecosystem activation, a demo day/showcase event, final outcomes reporting, and peer engagement.

PHARMA (BIOTECH)

Attend BIO International Convention 2027 in Philadelphia.

MEDICAL DEVICES (MEDTECH)

Philadelphia medtech, provider, and payer ecosystem activation.

What You'll Learn, by Track

Both tracks share a common foundation in U.S. readiness, storytelling, and fundraising. Track-specific content, mentoring, and ecosystem moments are tailored to the distinct paths of therapeutics and devices. Content is finalized after selection to reflect each cohort's demonstrated needs.

Pharma

Therapeutics, cell & gene, platforms, drug discovery

- U.S. regulatory pathways and clinical strategy
- R&D capabilities enhancement
- Pharma partnering, business development, and pilot / POC design and advancement
- Investor storytelling and financing strategy
- Market access and reimbursement
- U.S. incorporation, hiring, and enterprise procurement
- BIO International Convention readiness and activation

Medical Devices

Devices, diagnostics, imaging, wearables, implantables

- U.S. commercialization and market-entry strategy
- FDA device pathways: 510(k), De Novo, PMA, Breakthrough
- Reimbursement and payer strategy
- Hospital procurement and value-analysis committees
- Clinical champion and KOL development
- Pilot / POC design and evidence generation
- Medtech corporate partnerships; LSI USA '27 activation

WHAT EVERY FOUNDER BUILDS

COMMERCIALIZATION FLUENCY

A working command of U.S. market access, regulatory and reimbursement strategy, and the go-to-market decisions that determine value.

A HIGH-VALUE NETWORK

Direct, curated relationships with investors, pharma and medtech corporates, clinical leaders, and operators who move markets.

VALIDATED PATHWAYS

Qualified, active pathways to partnership and investment, pressure-tested against the U.S. market and ready to advance.

ECOSYSTEM ENGAGEMENT

The three in-person moments place founders inside the U.S. life sciences hubs that matter most for pharma and medical devices growth.

JANUARY

Boston

The densest life sciences cluster in the world, home to leading pharma, biotech, and medical devices companies, top research hospitals, and the venture capital that funds them. The launchpad for U.S. immersion and mentor relationships.

MARCH

San Diego

A premier hub for medical devices, diagnostics, and biotech, anchored by LSI USA '27 in Dana Point, one of the most important medtech investor and partnering convenings in the country.

JUNE

Philadelphia

A major cell and gene therapy and pharma corridor with a deep medical devices and health system provider base, and host of the BIO International Convention, the world's largest biotech partnering event, where the cohort activates and graduates.

THE COMMITMENT

DURATION

Pre-Kickoff + 6 Months

Pre-kickoff readiness followed by six months (January through June 2027), blending virtual acceleration with three in-person U.S. moments.

IN-PERSON • REQUIRED

3 U.S. trips

Boston (Jan), San Diego / LSI USA (Mar), and Philadelphia / BIO (Jun). At least one founder or senior executive must attend each.

ENGAGEMENT

Active participation

Bi-weekly mentor sessions, milestone deliverables, collateral development, and ongoing progress reporting.

PROGRAM GOALS • THROUGH THE FINALE AND 12 MONTHS AFTER

FINANCING

Raise next round of funding within 12 months.

PARTNERSHIP

Secure an enterprise partnership, pharma partnership, strategic collaboration, extended pilot, POC expansion, full rollout, or similar commercial opportunity facilitated or supported through the Program.

REGULATORY / REIMBURSEMENT

Achieve a stage-appropriate regulatory or reimbursement milestone.